Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's ...

Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy ...